Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates

Cancer Chemotherapy and Pharmacology

Volumn 53, Issue 1, 2004, Pages 39-42

  Renbarger, Jamie ^a   Aleksic, Alexander ^a   McGuffey, Leticia ^a   Dauser, Robert ^a   Berg, Stacey ^a   Blaney, Susan ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antiangiogenesis; Leptomeningeal malignancy; SU5416

Indexed keywords

SEMAXANIB;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG SCREENING; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LETHARGY; MALE; MEASUREMENT; MENINGIOMA; MONKEY; NONHUMAN; PLASMA CLEARANCE; PREDICTION; PRIMATE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME INHIBITORS; HALF-LIFE; INDOLES; INFUSIONS, INTRAVENOUS; MACACA MULATTA; MALE; PROTEIN-TYROSINE KINASES; PYRROLES;

EID: 0742269443     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0683-z     Document Type: Article

References (14)

1. Cropp G, Rosen L, Mulay M, Langecker P, Hannah A (1999) Pharmacokinetics and pharmacodynamics of SU5416 in a phase I, dose escalating trial in patients with advanced malignancies (abstract 619). Proc Am Soc Clin Oncol 18:161a
2. Donelli MG,, Zucchetti M, D'Incalci M (1992) Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 30:251-260
3. Ellis LM, Takahashi Y, Liu W, Shaheen RM (2000) Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 5 [Suppl 1]:11
4. Fong TAT, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99
5. Kuenen BC, Rosen L, Smit EF, Parson MRN, Levi M, Ruijter R, Huisman H, Kedde MA, Noordhuis P, van der Vijgh WJF, Peters GJ, Cropp GF, Scigalla P, Hoekman K, Pinedo HM, Giaccone G (2002) Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 20:1657
6. McCully C, Balis F, Bacher J, Phillips J, Poplack D (1990) Rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Anim Sci 40:520
7. McMahon G (2000) VEGF receptor signaling in tumor angiogenesis. Oncologist 5 [Suppl 1]:3
8. Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, Shaheen RM, Ellis LM, Weitman S, Shawver LK, Cherrington JM (2000) Development of SU5416, a selective small molecule inhibitor of the VEGF receptor tyrosine kinase activity, as an antiangiogenesis agent. Anticancer Drug Des 13:29
9. National Institutes of Health (1988) Guide for the care and use of laboratory animals. Department of Health, Education and Welfare (DHEW) publication (NIH) 85
10. Poplack DG, Bleyer WA, Wood JH, Kostolich M, Savitch JL, Ommaya AK (1977) A primate model for study of methotrexate pharmacokinetics in the central nervous system. Cancer Res 37:1982
11. Rosen L, Mulay M, Mayers A, Kabbinavar F, Rosen P, Cropp G, Hannah A (1999) Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies (abstract 618). Proc Am Soc Clin Oncol 18:161a
12. Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, McConkey DJ, McMahon G, Ellis LM (1999) Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 59:5412
13. Shargel L, Yu ABC (eds) (1999) Applied biopharmaceutics and pharmacokinetics. McGraw-Hill, New York
14. Sukbunterng J, Cropp G, Hannah A, Wagner GS, Shawver LK, Antonian L (2001) Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416. J Pharm Pharmacol 53:1629